The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments

被引:7
作者
Webb, Edward J. D. [1 ]
Meads, David M. [1 ]
Eskyte, Ieva [2 ]
Ford, Helen L. [3 ]
Bekker, Hilary L. [1 ]
Chataway, Jeremy [4 ,5 ]
Pepper, George [6 ]
Marti, Joachim [7 ]
Okan, Yasmina [8 ]
Pavitt, Sue H. [9 ]
Schmierer, Klaus [10 ,11 ]
Manzano, Ana [12 ]
机构
[1] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England
[2] Univ Leeds, Sch Law, Leeds, W Yorkshire, England
[3] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[4] UCL, Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat, UCL Queen Sq Inst Neurol,Fac Brain Sci, London WC1B 5EH, England
[5] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England
[6] ShiftMs, London, England
[7] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland
[8] Univ Leeds, Leeds Univ, Ctr Decis Res, Business Sch, Leeds, W Yorkshire, England
[9] Univ Leeds, Sch Dent, Dent Translat & Clin Res Unit, Leeds, W Yorkshire, England
[10] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Neurosci Surg & Trauma, London, England
[11] Barts Hlth NHS Trust, Royal London Hosp, Clin Board Med Neurosci, London, England
[12] Univ Leeds, Sch Sociol & Social Policy, Leeds, W Yorkshire, England
关键词
DISCRETE-CHOICE EXPERIMENTS; CONJOINT-ANALYSIS; PROFESSIONALS PREFERENCES; PATIENT PREFERENCES; PREGNANCY; THERAPIES; DIAGNOSIS; ATTRIBUTES; PEOPLE; TESTS;
D O I
10.1007/s40271-020-00429-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Relapsing-remitting multiple sclerosis (RRMS) is an incurable disease characterised by relapses (periods of function loss) followed by full or partial recovery, and potential permanent disability over time. Many disease-modifying treatments (DMTs) exist that help reduce relapses and slow disease progression. Most are contraindicated during conception/pregnancy and some require a discontinuation period before trying to conceive. Although around three-quarters of people with RRMS are women, there is limited knowledge about how reproductive issues impact DMT preference. Objective The aim of this study was to measure the preferences for DMTs of women with RRMS who are considering pregnancy. Design An online discrete choice experiment (DCE). Methods Participants chose between two hypothetical DMTs characterised by a set of attributes, then indicated if they preferred their choice to no treatment. Attributes were identified from interviews and focus groups with people with RRMS and MS professionals, as well as literature reviews, and included the probability of problems with pregnancy, discontinuation of DMTs, and breastfeeding safety. In each DCE task, participants were asked to imagine making decisions in three scenarios: now; when trying to conceive; and when pregnant. Analysis Two mixed logit models were estimated, one to assess the statistical significance between scenarios and one in maximum acceptable risk space to allow comparison of the magnitudes of parameters between scenarios. Sample Women with RRMS who were considering having a child in the future, recruited from a UK MS patient register. Results Sixty respondents completed the survey. Participants preferred no treatment in 12.6% of choices in the 'now' scenario, rising significantly to 37.6% in the 'trying to conceive' scenario and 60.3% in the 'pregnant' scenario (Kruskal-Wallisp < 0.001). This pattern corresponds with results from models that included a no-treatment alternative-specific constant (ASC) capturing differences between taking and not taking a DMT not specified by the attributes. The ASC was lower in the trying to conceive scenario than in the now scenario, and lower still in the pregnant scenario, indicating an intrinsic preference for no treatment. Participants also placed relatively less preference on reducing relapses and avoiding disease progression in the trying to conceive and pregnant scenarios compared with a lower risk of problems with pregnancy. In the trying to conceive scenario, participants' preference for treatments with shorter washout periods increased. Conclusion Women with RRMS considering having a child prefer DMTs with more favourable reproduction-related attributes, even when not trying to conceive. Reproductive issues also influenced preferences for DMT attributes not directly related to pregnancy, with preferences dependent on the life circumstances in which choices were made. The design of the DCE highlights the benefits of considering the scenario in which participants make choices, as they may change over time.
引用
收藏
页码:583 / 597
页数:15
相关论文
共 50 条
[31]   Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression [J].
Prosperini, Luca ;
Haggiag, Shalom ;
Tortorella, Carla ;
Galgani, Simonetta ;
Gasperini, Claudio .
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (09) :1391-1402
[32]   Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies [J].
Talente, Bari ;
Finseth, Lisbet ;
Blake, Natalie ;
Costello, Kathleen ;
Schmidt, Hollie ;
Vandigo, Joe ;
Oehrlein, Elisabeth M. .
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2025, 17 :199-215
[33]   Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis [J].
Sabin, Julia ;
Salas, Elisa ;
Martin-Martinez, Jesus ;
Candeliere-Merlicco, Antonio ;
Hernandez, Francisco Javier Barrero ;
Torres, Ana Maria Alonso ;
Sanchez-Menoyo, Jose Luis ;
Borrega, Laura ;
Rodriguez-Rodriguez, Maria ;
Gomez-Gutierrez, Montserrat ;
Eichau, Sara ;
Hernandez-Perez, Miguel angel ;
Calles, Carmen ;
Fernandez-Diaz, Eva ;
Carmona, Olga ;
Orviz, Aida ;
Lopez-Real, Ana ;
Lopez-Munoz, Pablo ;
Rodriguez, Amelia Mendoza ;
Aguera-Morales, Eduardo ;
Maurino, Jorge .
PATIENT PREFERENCE AND ADHERENCE, 2024, 18 :1163-1171
[34]   COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues [J].
Chirap-Mitulschi, Ioan-Alexandru ;
Ghimus, Constantin ;
Chirap-Mitulschi, Andreea Raluca ;
Antoniu, Sabina Antonela ;
Dragomir, Raluca .
DRUGS OF TODAY, 2022, 58 (12) :605-620
[35]   Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019 [J].
Duchesneau, Emilie D. ;
Kinlaw, Alan C. ;
Jonsson Funk, Michele ;
Pate, Virginia ;
Lund, Jennifer L. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (04) :481-487
[36]   Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing-Remitting Multiple Sclerosis [J].
Alshamrani, Foziah Jabbar Gossab ;
Zafar, Azra ;
Alsawad, Rahmah Majed ;
Yasawy, Zakia ;
Shahid, Rizwana ;
Nazish, Saima ;
Shariff, Erum ;
Soltan, Nehad Mahmoud .
SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES, 2024, 12 (04) :299-305
[37]   The impact of sociodemographic characteristics on diagnosis and access to disease-modifying treatment for patients with multiple sclerosis in Morocco [J].
Lotfi, Rachid ;
Chigr, Fatiha ;
Najimi, Mohamed .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
[38]   Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study [J].
Perez Sempere, Angel ;
Vera-Lopez, Vanesa ;
Gimenez-Martinez, Juana ;
Ruiz-Beato, Elena ;
Cuervo, Jesus ;
Maurino, Jorge .
PATIENT PREFERENCE AND ADHERENCE, 2017, 11 :995-999
[39]   Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies [J].
Bizon, Anna ;
Chojdak-Lukasiewicz, Justyna ;
Koltuniuk, Aleksandra ;
Budrewicz, Slawomir ;
Pokryszko-Dragan, Anna ;
Piwowar, Agnieszka .
ANTIOXIDANTS, 2022, 11 (12)
[40]   Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides [J].
Dungan, Lara ;
Dunne, Jean ;
Savio, Michael ;
Kalaszi, Marianna ;
Mcelheron, Matt ;
Lynagh, Yvonne ;
O'Driscoll, Kate ;
Roche, Carmel ;
Qureshi, Ammara ;
Crowley, Brendan ;
Conlon, Niall ;
Kearney, Hugh .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (03)